BRPI0814363A2 - Produtos fármacos de interferon de liberação controlada e tratamento de infecção por hcv usando os mesmos - Google Patents

Produtos fármacos de interferon de liberação controlada e tratamento de infecção por hcv usando os mesmos

Info

Publication number
BRPI0814363A2
BRPI0814363A2 BRPI0814363-3A2A BRPI0814363A BRPI0814363A2 BR PI0814363 A2 BRPI0814363 A2 BR PI0814363A2 BR PI0814363 A BRPI0814363 A BR PI0814363A BR PI0814363 A2 BRPI0814363 A2 BR PI0814363A2
Authority
BR
Brazil
Prior art keywords
interferon
same
controlled release
hcv infection
release drug
Prior art date
Application number
BRPI0814363-3A2A
Other languages
English (en)
Inventor
David Gelvin Spencer
John Elliot Humphries
Leonardus Gerardus Jozef De Leede
Rudolf Verrijk
Original Assignee
Biolex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolex Therapeutics Inc filed Critical Biolex Therapeutics Inc
Publication of BRPI0814363A2 publication Critical patent/BRPI0814363A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0814363-3A2A 2007-07-25 2008-07-25 Produtos fármacos de interferon de liberação controlada e tratamento de infecção por hcv usando os mesmos BRPI0814363A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95187907P 2007-07-25 2007-07-25
US95214007P 2007-07-26 2007-07-26
US97833007P 2007-10-08 2007-10-08
US98552607P 2007-11-05 2007-11-05
PCT/US2008/071191 WO2009015336A2 (en) 2007-07-25 2008-07-25 Controlled release interferon drug products and treatment of hcv infection using same

Publications (1)

Publication Number Publication Date
BRPI0814363A2 true BRPI0814363A2 (pt) 2015-01-27

Family

ID=40282165

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814363-3A2A BRPI0814363A2 (pt) 2007-07-25 2008-07-25 Produtos fármacos de interferon de liberação controlada e tratamento de infecção por hcv usando os mesmos

Country Status (11)

Country Link
US (1) US8137661B2 (pt)
EP (1) EP2175865A4 (pt)
JP (1) JP2010534681A (pt)
KR (1) KR20100056479A (pt)
CN (1) CN101820887A (pt)
AU (1) AU2008279087A1 (pt)
BR (1) BRPI0814363A2 (pt)
CA (1) CA2694440A1 (pt)
MX (1) MX2010000965A (pt)
WO (1) WO2009015336A2 (pt)
ZA (1) ZA201000681B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2346329B1 (en) * 2008-10-09 2013-08-21 Anadys Pharmaceuticals, Inc. A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
JP2013542983A (ja) 2010-11-19 2013-11-28 ヴィーナス・レメディーズ・リミテッド 標的薬物送達のための新規コンジュゲート
WO2013059638A1 (en) 2011-10-21 2013-04-25 Abbvie Inc. Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
CN103826627B (zh) 2011-10-21 2016-02-24 艾伯维公司 包含至少两种直接抗病毒剂和利巴韦林的组合物在制备治疗hcv的药物中的用途
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US20140363396A1 (en) * 2012-02-01 2014-12-11 Kadmon Pharmaceuticals Llc Once daily treatment of hepatitis c with ribavirin and taribavirin
WO2013168179A2 (en) * 2012-04-03 2013-11-14 Rubicon Research Private Limited Controlled release pharmaceutical formulations of antiviral agents
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410697B1 (en) * 1979-04-20 2002-06-25 Schering Corporation Process for purifying human leukocyte interferon
US6835557B1 (en) * 1980-01-08 2004-12-28 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human interferon-like polypeptides
US6610830B1 (en) * 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
US4749576A (en) * 1984-05-10 1988-06-07 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US6387365B1 (en) 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
JP2000507917A (ja) * 1995-11-02 2000-06-27 シェーリング コーポレイション 持続的低用量サイトカイン注入治療
US5980948A (en) 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
KR20010022007A (ko) * 1997-07-18 2001-03-15 추후보정 생물학적 활성 물질의 서방용 생분해성 마크로머
ES2162393T3 (es) 1997-09-21 2001-12-16 Schering Corp Terapia de combinacion para erradicar el hcv-rna detectable en pacientes con infeccion de hepatitis c cronica.
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
TWI277424B (en) 1998-05-15 2007-04-01 Schering Corp Combination therapy for eradicating detectable NCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6194006B1 (en) * 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US20030206928A1 (en) * 1999-04-07 2003-11-06 Pertti Tormala Bioactive, bioabsorbable surgical polyethylene glycol and polybutylene terephtalate copolymer composites and devices
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
CN1451048A (zh) * 2000-07-31 2003-10-22 比奥莱克斯公司 在浮萍中表达生物活性多肽
US7959910B2 (en) * 2000-07-31 2011-06-14 Biolex Therapeutics, Inc. C-terminally truncated interferon alpha variants
GB0018968D0 (en) 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
JP2005510521A (ja) 2001-11-12 2005-04-21 アルカーメス コントロールド セラピューティクス，インコーポレイテッド 生体適合性ポリマーブレンドおよびその使用
KR100856819B1 (ko) 2003-01-28 2008-09-05 아카데미슈 지켄후이스 라이덴 Ｌｌ―37 유래의 펩티드성 독소 억제제
US20050269364A1 (en) * 2004-04-30 2005-12-08 Gibson Rayce D Inflatable seal for bin discharge system
EP1621205A1 (en) 2004-07-28 2006-02-01 OctoPlus Technologies B.V. Antimicrobial peptides derived from CAP18
EP1679065A1 (en) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
WO2007002639A2 (en) * 2005-06-24 2007-01-04 Migenix Inc. Non-nucleoside anti-hepacivirus agents and uses thereof
DK1976516T3 (da) * 2006-01-09 2013-07-15 Romark Lab Lc Behandling af viral hepatitis

Also Published As

Publication number Publication date
US8137661B2 (en) 2012-03-20
WO2009015336A2 (en) 2009-01-29
US20090068280A1 (en) 2009-03-12
AU2008279087A1 (en) 2009-01-29
WO2009015336A3 (en) 2009-03-19
EP2175865A2 (en) 2010-04-21
JP2010534681A (ja) 2010-11-11
KR20100056479A (ko) 2010-05-27
CN101820887A (zh) 2010-09-01
EP2175865A4 (en) 2012-01-11
MX2010000965A (es) 2010-03-09
ZA201000681B (en) 2013-07-31
CA2694440A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
BRPI0814363A2 (pt) Produtos fármacos de interferon de liberação controlada e tratamento de infecção por hcv usando os mesmos
ZA201001585B (en) Spiropyrrolidines and their use against hcv and hiv infection
ATE522216T1 (de) Verwendung von 2-6-(3-amin-piperidin-1-yl)-3- methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1- ylmethyl-4-fluor-benzonitril zur behandlung von diabetes, krebs, autoimmunerkrankungen und hiv- infektionen
NO20070988L (no) Vaksine for forebygging og behandling av HIV-infeksjon
BRPI0807544A2 (pt) Sólido farmacêutico e dose de vacina
AP2009005070A0 (en) Antiviral drugs for treatment or prevention of dengue infection
EP2120566A4 (en) COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRUS INFECTIONS
EP2223934A4 (en) METHOD FOR INHIBITING A GRIPPEVIRUS INFECTION, AND MEDICAMENT THEREFOR
DK2155758T3 (da) Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer
BRPI0822625A2 (pt) "dispositivo espaçador modular para o tratamento de infecções por próteses"
DK1983964T3 (da) Anordning til indgivelse af lægemiddel
PL1951272T3 (pl) Zastosowanie lactobacillus do leczenia infekcji wirusowych
BRPI0715396A2 (pt) Vacinas de matriz proteíca e processos de produção e de administração de tais vacinas
IL199152A (en) Annals 2 - (piperidine-4-ram) -4-phenoxy or phenylamino-pyrimidine, containing and containing pharmaceutical preparations for the preparation of viral infections
IL200432A (en) Human antibodies against hepatitis C virus and their uses
AP2081A (en) Oligomeric peptides and their use for the treatment of HIV infections
DK1835907T3 (da) Lægemidler til behandling eller forebyggelse af fibrotiske sygdomme
IS7564A (is) Lyfjablanda með breytta losun
IL202450A (en) Pharmaceutical composition to treat influenza virus infection
ATE533774T1 (de) Neuartige nukleosidanaloge zur behandlung von virusinfektionen
EP1765330A4 (en) PYRANOINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DISEASE OR INFECTION CAUSED BY HEPATITIS C VIRUS
EP2224943A4 (en) USE OF A HUMAN ANTIBODY TO NEUTRALIZE HEPATITIS B VIRUS FOR THE PREVENTION OR TREATMENT OF HEPATITIS B INFECTIONS
GB2411354B (en) Use of Scutellaria for the treatment of viral infections
EP2120988A4 (en) TREATMENT OF HEPATITIS C VIRUS INFECTIONS
DK3156057T3 (da) Delmopinol-belagt dyretyggeartikel til anvendelse til forebyggelsen eller behandlingen af halitosis

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.